Medivir is a pharmaceutical company focusing on the development of innovative treatments for cancer.
Medivir focuses on cancers of high unmet medical need to provide benefit to patients who so far have had few treatment options.Our projects >
Medivir leverages collaborations with academic and industrial partners in order to bring specialty knowledge, experience and other capabilities to our projects.Partnership >
Medivir has completed the dose escalation part (phase 1b) of the 1b/2a study in HCC and focuses on the combination of fostrox and LenvimaRead more
Medivir to present at the Redeye Growth DayRead more
Change in the number of shares and votes in Medivir AB (publ)Read more
Partnering is an important element of our business strategy. Together with our partners we have been successful in taking two products from research, through clinical development to launch on a global scale.